PsiloThera, Inc.
Psychedelic Healthcare Innovation
Henderson, NV
Biotechnology
Psilothera is a pioneering mental health care company dedicated to creative, modern solutions to treat global healthcare concerns, including depression, anxiety, PTSD, eating disorders, addictions, Alzheimer’s, dementia, and more. We plan to deploy quantum technology to shorten the drug development time, which will give us an advantage over our competitors. With a focus on healing, hope, and compassion, we aim to change the paradigm of mental healthcare with their Psilocybin-based therapies.
$173,121
raised
164
Investors
$50M
Valuation
$5.00
Price per Share
$500.00
Min. Investment
Common
Shares Offered
Equity
Offering Type
$5M
Offering Max
0
Days Left
This offering ended on March 19, 2022 and is no longer accepting investments.
Reasons to Invest
Psilothera is stepping into the scene of major healthcare crisis by focusing on medical research breakthroughs and groundbreaking legalizations
The company is actively targeting a $100 billion market opportunity in Psilocybin healthcare
Psilothera is led by a battle tested management team with business model, strategy and plan driven by research and development
The Problem
The world is in the throes of a mental health crisis
Recent estimates from the World Health Organization show that roughly 322 Million People suffer from Major Depression Disorder. In the US alone, 16 million people suffer from this debilitating disease. What’s worse is that up to a third of the people suffering from clinical depression are “treatment resistant,” meaning traditional antidepressants don’t treat them. This resistance is one of the reasons why 17.6 veterans commit suicide a day in the United States. With the current state of the mental healthcare industry, they have no other options for medication.
A recent Gallup poll shows that the pharmaceutical industry is the least trusted industry in America. Toxic industry norms, widespread corruption, as well as harsh side effects of mental health medicine have created a need for a viable alternative among patients and consumers. (Source)
THE SOLUTION
Psilocybin-based therapy is revolutionizing the world of mental healthcare
Psilothera commits to providing new remedies for mental wellness by creating compounds for Psilocybin-based treatments. Psilocybin assisted therapy gives the patient the opportunity to fully engage in self-reflection and personal expression, ultimately shift emotional and behavior patterns.
The technique used in Psilocybin assisted therapy is microdosing. Microdosing is the regular intake of very small quantities of psychedelic substances. Microdosing is beneficial because while there are minimal acute effects reported, these substances claim a range of long-term health and well-being benefits. We believe the fear of having a “bad trip” on Psilocybin makes microdosing a more approachable option for the millions of people suffering.
THE MARKET
Vertical integration powered by quantum technology
Psilothera’s battle tested leadership team is made up of entrepreneurs, mental health professionals, and mushroom farmers. This team agrees on the same mission: be one of the first companies focused on developing Psilocybin-based therapeutics while deploying quantum technology. We are currently in the final stages of procuring a technology licensing agreement with a well-known quantum technology company, which will drastically reduce the development time as well as the cost of therapeutics.
OUR TRACTION
Gaining momentum by the day
Breakthrough studies by reputable programs such as Journal of JAMA Psychiatry, Johns Hopkins Center for Psychedelic & Consciousness Research, Imperial College, and US National Library of Medicine National Institute of Health have all shown promising results on psychedelics’ ability to treat long-lasting depressive, PTSD, and anxiety symptoms with minimal side effects.
Psilothera’s partnership with the Zoom Healthcare ISV Program to develop its tele-health mental health care video platform is paving the way for groundbreaking development in online Psilocybin-based treatment.
Psilothera is pre-revenue and our Fungi Grow & Lab is in its pre-launch stage. Once launched, the lab will begin researching, growing, and developing 20 different types of Psilocybe Cubensis, providing us with a robust portfolio of therapeutic fungi.
The varieties of mushrooms to be used in our formulations include Reishi, Lion’s Mane, Turkey Tail, Shiitake, Maitake, and Oyster. Reishi, for example, is being studied and used for its anticancer potential at the Memorial Sloan Kettering Cancer Center. Our Mushroom Nutraceutical product line for cancer patients is designed to support their current treatments program.
On a global scale, in November 2020, Oregon became the first state in the United States to legalize Psilocybin, allowing supervised use of psilocybin in a therapeutic setting.
Furthermore, voters around the country have decriminalized in Washington DC, Denver, Oakland, Ann Arbor, Houston, Somerset and Cambridge, MA so far. Psilothera projects widespread movement towards Legalization and Decriminalization by 2023.
WHY INVEST
The time to invest is now
A major paradigm shift is occurring in the healthcare sector. Breakthrough medical studies, a string of groundbreaking legalizations, and an unprecedented public openness to psychedelics has paved the road for Psilocybin-based therapy to be a legitimate alternative to pharmaceutical products. Psilothera aims to deploy this cutting edge medicine to establish itself as a beacon of hope, wellness, and compassion in the mental health market.
gif
Annual sales for antidepressants, ADHD, anxiety, and anti-addiction medications well exceed $30 billion, and an increasing number of studies are showing a potential for Psilocybin and other psychedelic-based therapies to be as or even more effective than their pharmaceutical counterparts, meaning potential billions in revenue.
Our mushrooms aren't magic. They're therapeutic, backed by science. We believe they're the future of mental health treatment.
Offering Summary
Company | : | PsiloThera, Inc. |
Corporate Address | : | 17 Cerchio Basso, Henderson, NV 89011 |
Offering Minimum | : | $10,000.00 |
Offering Maximum | : | $5,000,000.00 |
Minimum Investment Amount(per investor) | : | $500.00 |
Terms
Offering Type | : | Equity |
Security Name | : | Common Stock |
Minimum Number of Shares Offered | : | 2,000 |
Maximum Number of Shares Offered | : | 1,000,000 |
Price per Share | : | $5.00 |
Pre-Money Valuation | : | $50,000,000.00 |
*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below. Note these perks do stack with the other offering perks. You will only receive the highest level bonus share perk you are eligible for.
Company Perks*
Time-Based Perks
Friends & Family Bonus
Invest in the first 72 hours and receive 10% bonus shares.
Amount-Based Perks
Tier 1: $50,000+
Invest $50,000 or more and receive 5% bonus shares
Tier 2: $75,000+
Invest $75,000 or more and receive 7% bonus shares
Tier 3: $100,000+
Invest $100,000 or more and receive 10% bonus shares
*All perks occur when the offering is completed.
The 10% StartEngine Owners' Bonus
Psilothera will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.
This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $5.00 / share, you will receive 110 shares of Common Stock, meaning you'll own 110 shares for $500. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.
This 10% Bonus is only valid during the investors' eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are cancelled or fail.
Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.
Irregular Use of Proceeds
The Company will not incur any irregular use of proceeds.
Show More
Most recent fiscal year-end:
Prior fiscal year-end:
Total Assets
$0.00
USD
$0.00
USD
Cash And Cash Equivalents
$0.00
USD
$0.00
USD
Accounts Receivable
$0.00
USD
$0.00
USD
Short Term Debt
$0.00
USD
$0.00
USD
Long Term Debt
$0.00
USD
$0.00
USD
Revenues And Sales
$0.00
USD
$0.00
USD
Costs Of Goods Sold
$0.00
USD
$0.00
USD
Taxes Paid
$0.00
USD
$0.00
USD
Net Income
$0.00
USD
$0.00
USD
Risks
A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.
Updates
Psilothera + PolarisQB Sign Agreement to Launch Quantum, Ai + Machine Learning Technologies for Drug Discovery Platform.
7 months agoPsilothera Important Update
Thanks to all Investors
Psilothera + PolarisQB Sign Agreement to Launch Quantum, Ai + Machine Learning Technologies for Drug Discovery Platform.
Our treatment focus is Mental Illnesses and Cognitive Diseases.
According to Psilothera CEO, John Atanasio, "Polaris QB is an important Strategic Relationship & Resource of Psilothera's Drug Discovery & Development Platform."
Atanasio stated , "We shall deploy Polaris QB's Quantum Computing ,Ai + Machine Learning Technologies to identify unique opportunities for molecular discovery."
According to PolarisQB,
"We have built the first ever drug discovery platform using a quantum computer, making the discovery process ten times faster. Our platform and technology allow us to scan billions of molecules from a large chemical space, while keeping costs efficient.Without the need for multiple optimization cycles, we find the same (or better) molecules faster utilizing Quantum Computing, artificial intelligence, and machine learning."
Utah Senate Approved Psychedelic & Mental Health Bill - sent to Governor
7 months agoUtah Senate on Friday approved a psychedelic and mental health bill that would create a Mental Illness Psychotherapy Drug Task Force to study and make recommendations on the therapeutic potential of psychedelic drugs. The bill, which is now heading to the governor’s desk for a signature, would also establish possible regulations for the legal use of psychedelic drugs Source Bezinga
Utah is added to a list of States that have recently intiated a legislative process that includes: California, New York, Florida Hawaii. Oregon has already decriminalized and legalized for Therapeutic use. Denver, Houston, Washington DC are among the earliest cities to decriminalize.
Psilothera Drug Discovery Pipeline- Target Receptors
7 months ago
Phase 1 Drug Discovery Platform
Diagnosis/ Serotonin Receptor (s)Targets
PTSD: 5HT2A
DEPRESSION: 5HT2AR, 5HT2A
ANXIETY: 5HT2A, 5HT1A, 5HT2C
ANOREXIA NERVOSA:5-HT2A, 5-HT1A, 5-HT2C
ANXIETY CO-MORBIDITY: 5HT2A, 5HT1A, 5HT2C
DEPRESSION CO-MORBIDITY: 5HT2AR, 5HT2A
OCD: 5HT1A, 5HT2A, 5HT2C
ADDICTIONS: 5HT2AR
AUTISTIC SPECTRUM DISORDER: 5-HT2A, 5-HT1A
ANXIETY CO-MORBIDITY: 5HT2A, 5HT1A, 5HT2C
SUBSTANCE USE DISORDER:5HT2A, 5HT2C
ANXIETY CO-MORBIDITY: 5HT2A, 5HT1A, 5HT2C
ALCOHOL USE DISORDER: 5HT2A
TOBACCO USE DISORDER: 5HT2A
END-OF-LIFE ANXIETY: 5HT2A, 5HT1A, 5HT2C
ALZHEIMER’S, DEMENTIA, COGNITIVE DECLINE: 5HT2A-R
Data currently being collected on Cocaine, Opioids and Methamphetamine
Chuck Atanasio, Director of Research
Notice of Material Change in Offering
9 months ago[The following is an automated notice from the StartEngine team].
Hello! Recently, a change was made to the PsiloThera, Inc. offering. Here's an excerpt describing the specifics of the change:
The issuer is extending their campaign 59 days to 03/18/2022.
When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.
Psilothera & PsyRx Sign Important Agreement to Develop Natural Psychedelic Compounds
10 months agoHi Psilothera Investors,
Important Announcement
Psilothera & PsyRx Sign Agreement to Develop Natural Psychedelic Compounds.
PsyRx labs are located at Hebrew University in Tel Aviv, Israel and are licensed to develop naturally sourced Psychedelic Compounds. We shall collaborate with PsyRx to create GMP-Standard naturally sourced (Not Synthesized) Psilocybin, Ibogaine and other Psychedelic compounds when available using PsyRx’s Agro-Medical Bio Reactor.
Psilothera shall utilize these compound to develop innovative Therapeutics and treatments for Mental Illnesses and Cognitive Diseases.
John Atanasio, CEO
Psilothera Signs Agreement with Famous Shaman Inka Medicine Men to launch a healing retreat in Cuzco-Machu Picchu
10 months agoHi Psilothera Investors,
Psilothera gaining great traction in the market after our Wonderland- Miami Sponsorship. We are proud to announce this important company opportunity.
Psilothera is expanding into additional areas of Psychedelics beyond Psilocybin and is now looking at integrating other treatment options such as Ketamine, MDMA, DMT and LSD. The company plans to apply for a DEA Schedule 1 license for research and manufacturing.
Psilothera has signed an Agreement with Famous Shaman Inka Medicine Men to launch a Psilothera healing retreat in Cuzco-Machu Picchu.
Psilothera has exclusivepartnered with internationally recognized Shaman Inka Medicine Man K’uychi Florez Zevallos and his Son Luciano Florez Qquesihuallpa whom is a Psychologist and Shaman Inka Medicine Man.
K´uychi (Called Rainbow in his native Inka tongue “Quechua”) Born in Cusco, Peru. K’uychi holds an authentic blood and Inka lineage. K´uychi is a Shaman Inka Medicine Man, spiritualist, mystic, historian, researcher, poet and Peruvian politician. Since 1987, he has developed conferences and workshops throughout Asia, America and Europe. He is a University Professor, Master in Sciences who investigates and practices alternative therapies in a transpersonal, shamanic and holistic context. For the last 20 years, he´s been taking many groups of people to the jungle of Peru, leading them in shamanic experiences to treat and cure their mental and emotional illnesses, using the ancient jungle medicine, the sacred vine Ayahuasca DMT. Hundreds of people have awaken new states of consciousness, experienced a spiritual growth, enjoyed a new wellbeing and have discovered the real meaning of transcendence in their lives through the ceremonies and sacred rituals led by him. Nowadays K´uychi dedicates his great efforts to achieve the legitimacy of the legal therapeutic use of the DMT, and to stop the stigmatization of this divine plant that Mother Nature “Pachamama” with her immense love, has given to us, to whole humanity. His life’s mission is to spread the wisdom and medicine of the ancient Inka healers in all over the world. As shamans, we consider that DMT “The molecule of God” is one of the most powerful psychedelic that exist, its healing properties are limitless. DMT not only reaches your mind, goes even further into your heart and soul.
Please support our efforts and invest!
John Atanasio, CEO
Psilothera CEO John Atanasio to Speak at The Cannabis Investment Summit.- Feb 2nd
10 months agoHi Psilothera Investors
Psilothera CEO John Atanasio to Speak at The Cannabis Investment Summit.- Feb 2nd. Happy to be invited and this gives Psilothera another platform to share our story.
John Atanasio, CEO
Notice of Funds Disbursement
10 months ago[The following is an automated notice from the StartEngine team].
Hello!
As you might know, PsiloThera, Inc. has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PsiloThera, Inc. be on the lookout for an email that describes more about the disbursement process.
This campaign will continue to accept investments until its indicated closing date.
Thanks for funding the future.
-StartEngine
Psilothera to Present at the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference - December 6, 2021.
10 months agoHi Startengine Investors,
Psilothera to Present at the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference - December 6, 2021.
This is a great platform to share our story.
We have over 400 investors watching on the Startengine.
We have outstanding momentum and please invest now.
John Atanasio, CEO
Psilothera's CEO John Atanasio on Stage at Wonderland Miami 2021-Video
11 months agoHi StartEngine Investors
Psilothera's CEO John Atanasio on Stage at Wonderland Miami 2021 Video
{{ profileCtrl.commentsLoading ? 'Loading...' : 'Show More Comments' }}